E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10060862 |
E.1.2 | Term | Prostate cancer |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the difference in rate of treatment failure associated with observed progression of disease from low risk prostate cancer to moderate or higher risk prostate cancer in men who undergo TOOKAD® Soluble VTP compared to men on active surveillance. |
|
E.2.2 | Secondary objectives of the trial |
To assess the impact of TOOKAD® Soluble VTP on the rate of absence of significant cancer (key secondary objective).
To determine the differences between men who undergo TOOKAD® Soluble VTP and men on active surveillance with regard to: - the rate of additional prostate cancer therapy - the overall cancer burden in the prostate - Prostate Specific Antigen - the rate of adverse events - incontinence, erectile dysfunction, urinary and rectal discomfort - the overall quality of life and prostate-related anxiety |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Low risk prostate cancer diagnosed using transrectal ultrasound guided biopsy using a minimum of 10 cores or equivalent, showing: • Clinical stage up to T2a (pathological or radiological up to T2c disease permitted), • Gleason 3 + 3 prostate adenocarcinoma, • A maximum of three (3) cores positive for cancer, • A maximum cancer core length of 5 mm in any core. 2) Serum prostate specific antigen (PSA) of 10 ng/mL or less. 3) Prostate volume more than 30 cc and less than 60 cc. 4) Male subjects aged 18 years or older. |
|
E.4 | Principal exclusion criteria |
1) Unwillingness to accept randomisation to either of the two arms of the study 2) Any prior or current treatment for prostate cancer, including surgery, radiation therapy (external or brachytherapy) or chemotherapy. 3) Life expectancy less than 5 years. 4) Any condition or history of illness or surgery that may pose an additional risk to men undergoing the VTP procedure such as: 4.1) Any condition or history of illness or surgery that in the opinion of the Investigator might affect the conduct and results of the study or pose additional risks to the subject (e.g., active inflammatory bowel disease which may predispose to rectal fistula formation, cardiac or respiratory disease precluding general anaesthesia; anticoagulant treatment which cannot be temporarily withdrawn for the procedure); 4.2) Medical conditions which preclude the use of general anaesthesia. 4.3) A history of active rectal inflammatory bowel disease or other factors which may increase the risk of fistula formation. 4.4) Hormonal manipulation (excluding 5 alpha reductase inhibitors) or androgen supplements within the previous 6 months. 4.5) History of urethral stricture disease. 4.6) History of acute urinary retention within 6 months of study entry. 4.7) Men who have an absolute need for the following medication which have potential photosensitising effects (tetracyclines, sulphonamides, phenothiazines, sulfonylurea hypoglycaemic agents, thiazide diuretics and griseofulvin). 4.8) Men who have an absolute need for anticoagulant drugs or antiplatelet drugs (e.g., warfarin, aspirin) which cannot be withdrawn during the 10 days prior to the VTP procedure. 4.9) Renal and hepatic disorders with values of >1.5 times the upper limit of normal (ULN) and blood disorders (clinician judgement). 4.10) A history of sun hypersensitivity or photosensitive dermatitis. 5) Participation in another clinical study or recipient of an investigational product within 1 month of study entry. 6) Contra-indication to MRI (e.g., pacemaker), or factors excluding accurate reading of pelvic MRI (e.g., hip prosthesis).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Failure of treatment due to progression of cancer from low to moderate or higher risk over the 24 month follow-up. Moderate or higher risk is defined as the observation of: - More than 3 cores positive for cancer when considering all biopsies during follow-up of study; - or any Gleason primary or secondary pattern 4 or more; - or at least one cancer core length greater than 5 mm; - or PSA>10ng/mL in 3 consecutive measures; - or any metastasis.
Positive cores are considered whenever the length of cancer in the core is >1 mm in size. Histological changes are assessed using biopsies taken under the guidance of transrectal ultrasound at 12 and 24 months or at anytime time during follow-up.
A panel blinded to the exposure status reviews the histological reports of all patients, whether reported positive or negative for cancer, and all the PSA data.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Information not present in EudraCT |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Active surveillance population |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 19 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |